Navigation Links
New Anal Cancer Therapy Fails to Improve Outcomes
Date:4/22/2008

Experimental use of cisplatin no better than standard treatment, researchers say

TUESDAY, April 22 (HealthDay News) -- Compared to the standard treatment regimen for anal canal cancer, the use of the chemotherapy drug cisplatin before other treatments didn't improve disease-free survival and resulted in a higher rate of colostomy procedures, says a U.S. study.

Currently, the preferred primary therapy for patients with anal canal cancer is chemoradiation (concurrent use of radiation and the anti-cancer drugs fluorouracil/mitomycin), which achieves a five-year survival rate of about 65 percent, according to background information in the study.

It's been suggested that reducing cancer in the primary tumor and in the lymph node or nodes prior to chemoradiation might improve disease-free survival. Pilot studies using cisplatin prior to chemoradiation showed promise.

In this new, randomized controlled trial, Dr. Jaffer A. Ajani, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues compared treatment with fluorouracil plus mitomycin and radiation therapy to treatment with fluorouracil plus cisplatin and radiation therapy.

The findings from 644 patients showed a five-year, disease-free survival rate of 60 percent in the mitomycin group and 54 percent in the cisplatin group. The five-year overall survival rate was 75 percent in the mitomycin group and 70 percent in the cisplatin group. There were more cancer-related deaths in the cisplatin group (54) than in the mitomycin group (28).

The five-year, local-regional cancer recurrence and distant metastasis rates were 25 percent and 15 percent, respectively, for the mitomycin group and 33 percent and 19 percent, respectively, for the cisplatin group. Severe blood toxicity was worse in the mitomycin group. The cisplatin group had a higher rate of colostomy (19 percent vs. 10 percent).

"The question remains how to further improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin," the study authors wrote. "Options to explore included targeted agents (e.g., results with concurrent cetuximab plus radiation for head/neck cancer), dose escalation with intensity-modulated radiation plus concurrent chemotherapy, and surgical excision of residual cancer after concurrent chemoradiation at an earlier interval, when sphincter preservation may still be feasible in select patients."

The study was published in this week's issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about anal cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, April 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover a mechanism that can send cells on the road to cancer
2. Factors in Cancer Death Rates Stay Stagnant
3. Cancer Death Rates Stay Stagnant
4. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
5. Phone counseling improves quality of life, immune systems of cervical cancer survivors
6. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
7. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. American Cancer Society report details cancer prevention efforts
10. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology: